SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the FDA has approved its Wegovy pill, marking the first oral GLP-1 for weight management and cardiovascular risk reduction. The community widely views this as a "game changer" due to the convenience of a pill over injectables, anticipating significant market expansion and potential for substantial stock appreciation for the previously "undervalued" company.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining (HYMC) is currently trending due to recent drill results indicating high-grade silver in its Vortex system, fueling renewed optimism for its significant undeveloped gold and silver reserves. The community is actively discussing the immense potential of these deposits and the company's substantial institutional backing, notably from Eric Sprott, amidst a broader context of surging precious metal prices.

Starfighters Space Inc

Starfighters Space Inc. (FJET) is experiencing immense trading activity and volatility following its recent public debut, fueled by substantial price movement. Community discussion centers on whether it will be a multi-day runner, drawing parallels to other high-flying low-float IPOs, even as questions arise regarding its fundamental business model and operational scale. This aerospace firm, utilizing F-104 jets for satellite launches, is a key topic amid broader speculative interest in the space sector.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending due to its advanced GaN and SiC power solutions, which are critical for next-generation AI data centers and align with industry leaders like NVIDIA's 800VDC AI factory architecture. The community is actively discussing the stock's substantial short interest, sparking intense debate over potential market manipulation and the anticipation of a significant short squeeze.

Trump For President

TRUMP CRYPTO is trending due to intense community discussion surrounding the release of Jeffrey Epstein files, with many users speculating on former President Trump's alleged involvement and its potential impact. Sentiment is highly polarized, as critics label the token a "scam" and "shitcoin" amidst significant declines, while a smaller group of supporters expresses bullish optimism, often dismissing negative views as politically motivated.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Novo Nordisk's recent FDA approval of an oral GLP-1 for weight loss has ignited intense discussions around Viking Therapeutics, with many investors viewing it as a significant de-risking event for the oral obesity market. Community sentiment highlights VKTX's promising oral VK2735, which has demonstrated strong early efficacy and potentially superior tolerability compared to approved and emerging competitors. However, some express frustration over VKTX's stock performance and perceived management strategy amid escalating competition from pharmaceutical giants.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to its recent record of 21 successful Electron launches this year and securing an $816 million U.S. Space Development Agency contract, its largest award to date, positioning it as a key defense systems integrator. While some investors are taking profits and cautioning about high valuations amidst after-hours insider selling, the community largely views this as an "unstoppable" growth story, buoyed by broader space sector momentum and future catalysts like the Neutron rocket and ongoing discussions around a potential SpaceX IPO.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Tempe, AZ.

First Solar Inc

First Solar is a top trending stock following Alphabet's acquisition of Intersect Power, a significant customer, which is driving conversations around the increasing demand for solar energy to power AI data centers. The community is actively discussing FSLR's impressive breakout to new highs, fueled by its strong domestic manufacturing capabilities and advantageous long-term supply agreements. Multiple analysts are reiterating positive ratings and raising price targets, underscoring the company's strategic value in the evolving energy sector.

Applied Materials, Inc. engages in provision of materials engineering solutions used to produce semiconductors. The firm also focuses on design, development, production, and servicing of the critical wafer fabrication tools used for customers to manufacture semiconductors. It operates through the following segments: Semiconductor Systems and Applied Global Services (AGS). The Semiconductor Systems segment includes designing, development, manufacturing and sale of equipment used to fabricate semiconductor chips referred to as integrated circuits. The AGS segment engages in provision of services, spares, and factory automation software to customer fabrication plants globally. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending as discussions focus on its growth outlook, particularly concerning the impact of US-China export restrictions on its China-based business. Despite these geopolitical headwinds and a more cautious guidance, many in the community view AMAT as a key enabler of advanced chip manufacturing and AI, leading to debate over whether the current valuation presents a buying opportunity or signals ongoing challenges in the semiconductor equipment sector. Analysts are divided, with some highlighting its long-term potential in AI-driven silicon demand while others remain wary of near-term market conditions.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending amidst growing excitement for its merger target, Infleqtion, following recent partnerships with Safran for GPS-independent timing solutions and collaboration with Oak Ridge National Laboratory on quantum computing integration, underscoring its pivotal role in national security and defense. The community views Infleqtion's deployable quantum sensing technology and "real" revenue as significant differentiators, anticipating the upcoming merger will unlock further institutional interest and re-rate its valuation against other quantum sector players.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to Discuss Their Rights Halper Sadeh LLC Encourages QIPT, FITB, GBIO, APLT Shareholders to Contact the Firm to...

Here's Why Applied Therapeutics (APLT) Is a Great 'Buy the Bottom' Stock Now

Applied Therapeutics (APLT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT

SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT SHAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--ALEX, DVS, DXLG, and APLT...

APLT Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Applied Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Applied Therapeutics, Inc. (NASDAQ: APLT) to Cycle Group Holdings Limited for $0.088 per share in cash plus one...

Applied Therapeutics (APLT) Upgraded to Buy: Here's Why

Applied Therapeutics (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

<ul class="summary-bullets"><li>The company stated that there is no deadline for the strategic alternative finding process.</li><li>The firm also noted that it intends to request an additional meeting with the FDA to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency.</li></ul> Applied Therapeutics, Inc. (APLT) said on Thursday that it is laying off approximately 46% of its workforce as it seeks to conserve cash, while its Board of Directors explores strategic alternatives for the company.The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements, or other strategic transactions to maximise shareholder value, the company<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/20/3191771/0/en/Applied-Therapeutics-Announces-Corporate-Updates.html"> said</a>. There is no deadline for the process, Applied Therapeutics noted, while also adding that the review might not result in a transaction.<h2 class="st-heading-2">Drug Pipeline Updates</h2>The company also said it intends to request an additional meeting with the U.S. Food and Drug Administration to decide on a design for its late-stage study of Govorestat for the treatment of Charcot-Marie-Tooth Sorbitol Dehydrogenase (SORD) Deficiency. In this disorder, the body can’t properly metabolize sorbitol, leading to its toxic accumulation that damages peripheral nerves and causes progressive symptoms like limb weakness, numbness, and difficulty walking.The company held a meeting with the FDA in the third quarter and is now evaluating the meeting minutes and follow-up correspondence.It is also evaluating the next steps for developing Govorestat for the treatment of Classic Galactosemia, a disorder in which the body cannot break down the sugar galactose. &nbsp;Govorestat is the company’s lead drug candidate for the treatment of CNS rare metabolic diseases or inherited conditions affecting the brain, such as Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency, and phosphomannomutase 2 congenital disorder of glycosylation.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/APLT">APLT shares</a> traded marginally in the red at the time of writing. On Stocktwits, retail sentiment stayed within the ‘extremely bullish’ territory over the past 12 months while message volume stayed at ‘extremely high’ levels.APLT shares fell 67% this year and by 97% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/moderna-procures-1.5-billion-loan-to-grow-its-pipeline-beyond-vaccines/cLPA0dfREaR">Moderna Secures $1.5B Credit Facility As It Seeks To Pivot Away From Vaccines</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Applied Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Applied Therapeutics To Lay Off Nearly Half Its Staff, Board Explores M&A Options

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.

Equity

The board is considering mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions, the company said.


Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain

Applied Therapeutics stock falls after FDA feedback prompts another Type C meeting to discuss the Phase 3 plan for its CMT-SORD drug govorestat.read more...

Halper Sadeh LLC Encourages Applied Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Applied Therapeutics, Inc. (NASDAQ: APLT) breached their fiduciary duties to shareholders. If...

Retail buzz&nbsp;surrounding Applied Therapeutics Inc spiked&nbsp;late Sunday after the company revealed full 12-month clinical results alongside new 18- and 24-month topline data from&nbsp;a midstage trial of govorestat to treat Charcot-Marie-Tooth disease caused by Sorbitol Dehydrogenase deficiency (CMT-SORD).MRI observations showed that govorestat treatment slowed disease progression at 24 months, while keeping blood sorbitol levels low and improving functional outcomes and patient-reported metrics.The 12-month data revealed a statistically significant increase in the CMT-Health Index (CMT-HI) and a connection between sorbitol reductions and enhanced mobility and balance.&nbsp;CMT-SORD is a rare, progressive neuromuscular disorder that leads to nerve damage, muscle weakness, and mobility impairment.The company acknowledged that the primary endpoint of the 10MWRT at 12 months failed to show statistical significance, which led to its removal from the CMT-FOM clinical outcomes tool.Patients demonstrated good tolerance for govorestat, maintaining safety for two years.&nbsp;90% of eligible patients continued participating in the open-label extension study.&nbsp;Applied Therapeutics said it will submit a New Drug Application (NDA) for govorestat by 2025.The company’s shares surged 22.8% to close at $0.60 on Friday, with a further 1.2% gain in after-hours trading.On Stocktwits, retail sentiment was ‘extremely bullish’ amid ‘a 629% surge in 24-hour message volume.Some retail traders expressed optimism about Applied Therapeutics' prospects, with one suggesting that the stock’s sharp decline in December may have been overdone and that the current low valuation presents a “monster opportunity.”<stembedurl>https://stocktwits.com/BuyThemCheapStackemDeep/message/615044473</stembedurl>Another pointed to the positive impact of govorestat on disease progression in CMT-SORD, noting that in a rare condition with no approved treatments, the available data could support regulatory approval.<stembedurl>https://stocktwits.com/Aawilliam2003/message/615043651</stembedurl>The stock has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

A photo illustration showing a mix of various tablets and pharmaceutical products, primarily manufactured by U.S. pharmaceutical companies, photographed in Edmonton, Alberta, Canada, on April 10, 2025 (Photo by Artur Widak/NurPhoto via Getty Images)

Retail Traders Cheer Applied Therapeutics Data On Rare Nerve Disease Drug

The company said that Govorestat slowed disease progression and improved patient outcomes in CMT-SORD, a rare hereditary neuropathy. The company plans to submit an NDA in 2025 amid strong retail investor interest.

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Current Price	$0.1252
Prev Close	$0.125
Open	$0.125
Dividend Yield	0.00%
50-Day Moving Average	$0.6446
Beta	1.31
Avg. Volume	26.72M
PE Ratio	-1.25

52-Week High	$1.50
52-Week Low	$0.10
Market Capitalization	$18.04M
EPS (Annual)	-$0.757
Price to Book	-32.19
Revenue Per Employee	$13,000.00
Enterprise Value/EBITDA	N/A

APLT
Applied Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLT News

APLTApplied Therapeutics Inc